Orally Disintegrating Tablets Using Starch and Fructose - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Orally Disintegrating Tablets Using Starch and Fructose
The authors demonstrated that ODTs can be obtained by direct compression of a mixture of starch, fructose, and SMCC.

Pharmaceutical Technology
pp. 92-99


Increased concentration of the binder improved the compaction properties of the formulations. The use of SMCC allowed for more rapid disintegration times when compared with MCC. Moreover, because SMCC is less sensitive to the effect of lubricant, the SMCC-containing tablets are less friable and exhibit faster disintegration times. Among the different SMCC grades studied, the high average particle size and low bulk density, SMCC2 was the most effective tablet binder in terms of disintegration and friability. Fructose displayed superior flow characteristics and acceptable disintegration times at low tablet hardness. Furthermore, the use of fructose maintained good uniformity among tablet batches due to its good flow properties. Even though starch exhibited limited flow characteristics, it provided high porosity and rapid disintegration times at low, medium, and high tablet hardness. The mixture of fructose and starch displayed an optimal effect in terms of disintegration time, flow and tablet strength when combined in different ratios. The authors demonstrated that direct compression can be used in the manufacture of ODTs when SMCC was used in conjunction with a mixture of disintegrants that allowed for good flow, low friability and high tablet porosity.


Financial and material support for this work from Tate & Lyle Ingredients is gratefully acknowledged. Contribution of materials from JRS Pharma of Germany is also gratefully acknowledged.

Javier O. Morales is a graduate research assistant, Michelle Horng is an undergraduate research assistant, and Jason T. McConville* is an assistant professor at the University of Texas at Austin, College of Pharmacy, 1 University Station A1920, Austin, TX 78712, tel. 512.471.0942, fax 512.471.7474,
. Aubrey M. Gregg is a food technologist at Tate & Lyle Ingredients in Decatur, IL.

*To whom all correspondence should be addressed.

Submitted: Nov. 4, 2009. Accepted: Feb. 18, 2010.


1. S. Lindgren and L. Janzon, Med. Clin. North. Am. 77, 3–5 (1993).

2. G. Sandri et al., Am. J. Drug Del. 4 (4), 249–262 (2006).

3. FDA, Guidance for Industry: Orally Disintegrating Tablets (Rockville, MD, Dec. 2008).

4. W. Habib, R. Khankari, and J. Hontz, Crit. Rev. Ther. Drug Carrier Syst. 17 (1), 61–72 (2000).

5. D. Brown, Drug Del. Technol. 3 (6), 58–61 (2003).

6. L.V. Allen, N.G. Popovich, and H.C. Ansel, "Solutions" in Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. (Lippincott Williams & Wilkins, Baltimore, MD, 8th ed., 2005), pp. 337–339.

7. H. Seager, J. Pharm. Pharmacol. 50 (4), 375–382 (1998).

8. S.H. Jeong, and K. Park, Int. J. Pharm. 353 (1-2), 195–204 (2008).

9. A. Fini et al., Eur. J. Pharm. Biopharm. 69 (1), 335–341 (2008).

10. D.J. Gole et al., "Preparation of Pharmaceutical and Other Matrix Systems by Solid-State Dissolution," US Patent 5215756, 1993.

11. T. Mizumoto et al., "Tablets Quickly Disintegrating in the Oral Cavity and Process for Producing the Same," US Patent 6589554, 2003.

12. F. Wehling and S. Schuehle, "Base-Coated Acid Particles and EffervescentFormulation Incorporating Same," US Patent 5503846, 1996.

13. R.K. Khankari et al., "Rapidly Dissolving Robust Dosage Form," US Patent 6221392, 2001.

14. Y. Fu, et al., Crit. Rev. Ther. Drug Carrier Syst. 21 (6), 433–76 (2004).

15. M.J. Tobyn et al., Int. J. Pharm. 169 (2), 183–194 (1998).

16. S. Edge et al., Int. J. Pharm. 200 (1), 67–72 (2000).

17. S. Edge et al., Drug Dev. Ind. Pharm. 27 (7), 613–621 (2001).

18. B. van Veen et al. Eur. J. Pharm. Biopharm. 59 (1), 133–138 (2005).

19. S. Edge et al., Pharm. Pharmacol. Comm. 5 (6), 371–376 (1999).

20. B.E. Sherwood et al., Pharm. Tech. 22 (10), 78–88 (1998).

21. J. Mužíková and P. Nováková, Drug Dev. Ind. Pharma. 33 (7), 775–781 (2007).

22. M.K. Kottke and E.M. Rudnic, "Tablet dosage forms," in Modern Pharmaceutics, G.S. Banker and C.T. Rhodes, Eds. (Dekker, New York, NY, 4th ed., 2002), pp. 287–333.

23. K.B. Mulderrig et al., Pharm Technol. 24 (5), 34–44 (2000).

24. M.K. Kottke et al., Drug Dev. Ind. Pharma. 18 (20), 2207–2223 (1992).

25. S.C. Owen, "Fructose," in Handbook of Pharma. Excip., R.C. Rowe, P.J. Sheskey, and P.J. Weller, Eds. (Pharm. Press, London, 5th ed., 2005), pp. 290–292.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here